iBio (IBIO) Stock Continues Up: Will It Last?

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is having yet another incredible start to the trading session, running on gains of more than 29% before the opening bell. The gains only add fuel to the fire as the stock has climed more than 900% in the last 30 days, most of which has happened in the last 3 trading sessions.

While the company hasn’t issued any news this morning, there’s a good reason for the gains. Investors see value in the treatment or prevention of the coronavirus, and IBIO has a double-edged sword in the fight. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Why Investors Are All Over IBIO

As of late, the stock market has been a rough place to be. In fact, most stocks have been taking a hit as the Wuhan Coronavirus, or COVID-19, leads to global fears of a pandemic. However, there is one class of stocks that has been consistently green as of late. Those are biotech stocks that are working on ways to combat COVID-19. This is where iBio comes in.

Not only is the company in the race to develop the first Wuhan coronavirus vaccine, it is well positioned to win in the space, no matter who comes up with the vaccine first. We’ll talk about that in a second. First, let’s talk about the work the company is doing to develop its own vaccine.

Recently, IBIO issued news announcing that it has teamed up with a Chinese biotech company by the name of CC Pharming. The collaboration centers around the creation of a vaccine.

The partnership has a competitive advantage here too. CC Pharming has developed multiple vaccines in the past. Of particular interest to me is the vaccine that the copany developed for SARS, another form of coronavirus. With success in SARS, it only makes sense that the company has a head start fighting against SARS’ cousin, the Wuhan coronavirus. However, that’s not the only reason I’m excited here.

A Win/Win

IBIO is in a very unique position at the moment that offers it a win/win opportunity. Of course, if the company’s partnership with CC Pharming results in the first or second approved COVID-19 vaccine, there’s plenty of money to be made, but the opportunity goes far beyond that.

A few years back, the company was part of a government sponsored program aimed at providing medical agents quickly in times of a pandemic. As part of the program, the company developed what’s known as the FastPharming Facility.

To my knowledge, iBio’s FastPharming Facility has the ability to manufacture vaccines at a much faster rate than other facilities out there. This is a key advantage.

After all, the Wuhan coronavirus is spreading quickly and the medical community is working quickly to combat it. So, it only makes sense that when a vaccine is created, the developer of the vaccine will want to get it to the masses quickly. To do so, their best option will be to team up with IBIO for manufacturing.

So, it doesn’t matter if iBio develops the vaccine or another company does, IBIO investors are likely to win!

Beware Of Profit Taking

The opportunity here is tremendous. However, the movement that we’ve seen out of the stock has been just as jaw dropping. Think about it, it’s not every day that you see 900%+ gains in a month.

With that said, at these levels, the institutional players may begin to start taking profits, putting a damper on the run. Be prepared for this to happen so that you can make reasonable moves when it does.

Nonetheless, even after the profit taking, the opportunity surrounding IBIO is tremendous!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.